Evidence map›Paper›PMID 33528791›Full record

ArticleJournal of molecular neuroscience : MN2021

UBE2R2-AS1 Inhibits Xenograft Growth in Nude Mice and Correlates with a Positive Prognosis in Glioma.

Wu Xu, Dan-Dan Che, Liang Chen, Sheng-Qing Lv, Jun Su, Jun Tan, Qing Liu, Ya-Wen Pan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Wu XuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Dan-Dan CheDepartment of Intensive Care Unit, Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518100, Guangdong, China.
Liang ChenDepartment of Neurosurgery, Affiliated Hospital of Jiujiang University, Jiujiang, 332000, Jiangxi, China.
Sheng-Qing LvDepartment of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Jun SuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Jun TanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Qing LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. liuqingdr@csu.edu.cn.ORCID http://orcid.org/0000-0002-7713-9372
Ya-Wen PanDepartment of Neurosurgery, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China. Panyawen666@sohu.com.
Central South University · CNJiujiang University · CNArmy Medical University · CNLanzhou University Second Hospital · CNSouthern University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous study showed that the lncRNA UBE2R2-AS1 inhibits the growth and invasion of glioma cells and promotes apoptosis through the miR-877-3p/TLR4 pathway. In this study, it was further found that the expression of UBE2R2-AS1 in glioma tissues was decreased significantly, and gradually decreased with increasing clinical stage. Chi-square analysis showed that the expression of UBE2R2-AS1 was significantly correlated with the WHO stage of tumor and epilepsy. Using Kaplan-Meier univariate survival analysis, it was found that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma, while multiple Cox regression analysis showed that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma as a protective factor for glioma prognosis. The analysis of data from TCGA also showed that patients with high UBE2R2-AS1 levels or low miR-877-3p expression were more likely to have good survival outcomes. Further construction of a glioma xenograft model in nude mice showed that UBE2R2-AS1 overexpression inhibited the growth of tumors, and the inhibition of miR-877-3p expression had a similar effect. Simultaneous UBE2R2-AS1 overexpression and miR-877-3p inhibition further decreased the growth rate of tumors in nude mice. Taken together, the results of our study suggest that UBE2R2-AS1 is an important tumor suppressor gene in glioma, which may be a good marker and treatment target for the clinical detection of glioma.

Indexed as

AnimalsBiomarkers, TumorBrain NeoplasmsFemaleGliomaHumansMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsMiddle AgedRNA, AntisenseUbiquitin-Conjugating EnzymesBiomarkers, TumorMicroRNAsMIRN877 microRNA, humanRNA, AntisenseUbe2R2 protein, humanUbiquitin-Conjugating EnzymesGliomalncRNAmiR-877-3pPrognosisUBE2R2-AS1

Identifiers

PMID33528791
OpenAlexW3128838519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.